Abcellera Biologics Inc (ABCL) — Capital Reinvestment Ratio
Latest as of June 2023:
1.38x
Abcellera Biologics Inc (ABCL) has a Capital Reinvestment Ratio of 1.38x as of June 2023, meaning it reinvests 1% of its operating cash flow ($19.82 Million) in capital expenditures ($27.35 Million). See Abcellera Biologics Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
1.38x
Capex / Operating Cash Flow
Operating Cash Flow
$19.82 Million
USD
Capital Expenditures
$27.35 Million
USD
Data as of
Jun 2023
Most recent filing
Abcellera Biologics Inc Capital Reinvestment Ratio (2018–2022)
This chart tracks Abcellera Biologics Inc's Capital Reinvestment Ratio across 5 annual periods.
Annual Capital Reinvestment Ratio for Abcellera Biologics Inc (2018–2022)
Year-by-year Capital Reinvestment Ratio for Abcellera Biologics Inc from 2018 to 2022. For live market cap and broader valuation context, see Abcellera Biologics Inc market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.26x | $277.36 Million | $72.66 Million | ▲ +9.6% |
| 2021 | 0.24x | $244.58 Million | $58.45 Million | ▼ -63.0% |
| 2020 | 0.65x | $22.69 Million | $14.67 Million | ▼ -56.4% |
| 2019 | 1.48x | $2.69 Million | $4.00 Million | ▼ -0.3% |
| 2018 | 1.49x | $3.56 Million | $5.31 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow